Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

HSBC upgrades Merck stock to Buy on 2025 opportunities

Source Investing

Investing.com -- HSBC (LON:HSBA) analysts raised their rating on Merck &Company Inc (NYSE:MRK) shares to Buy from Hold while maintaining a price target of $130.

The move comes amid a growing market confidence in the company’s ability to navigate through upcoming patent expirations. Merck (NS:PROR)'s credible strategy for dealing with the loss of exclusivity (LOEs) for key drugs later in the decade has been a contributing factor to the upgrade.

Merck's expertise in oncology and a rich clinical pipeline are seen as key strengths. The company's success in developing cancer treatments, particularly in the field of oncology, has been well-documented.

However, HSBC notes that the true value of Merck's pipeline is expected to be recognized only when early evidence of clinical success emerges, which is not yet reflected in current estimates and stock multiples.

One of the main opportunities identified for Merck in 2025 is the stabilization of Gardasil revenues in China, updates on subcutaneous Keytruda, and the launch trajectory of Winrevir.

“There is a dearth of significant readouts for Merck’s pipeline for 2025 that could change the trajectory of growth,” HSBC analysts said in a report.

“However, updates on Phase II Antibody-Drug Conjugates (ADC) assets might help the market appreciate the potential of these pipeline assets whilst including them in valuation and estimates,” they added.

Key risks for Merck in 2025, according to HSBC, include any signs of Gardasil's growth slowing in developed markets and challenges with the subcutaneous version of Keytruda. If these materialize, they could cast doubt on the market's expectation that Keytruda's patent cliff will level off rather than decline sharply.

The investment bank has adjusted its estimates for Merck downward to account for lower growth potential in Gardasil, particularly regarding its adoption in second-tier Chinese cities and among males.

Even with these revised estimates, HSBC believes that Merck's current valuation offers a significant margin of safety, “especially given its strategy to extend its oncology portfolio’s earning potential in the medium term,” analysts noted.

Looking ahead to the first half of 2025, the bank notes that there may be few clinical catalysts capable of significantly changing Merck's equity story. Nonetheless, Keytruda combination clinical trials could help the company maintain its volume and revenue share in the immuno-oncology market.

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

Dollar holds above 100 near a 3-month high — three Fed speakers and a $69 billion auction land tonight The dollar index closed at 100.43 on Monday, its highest close since late July, after a weekly gain of about 1% — the best in more than three months — and is holding above the 100.00 handle in Asia. Three Fed officials speak tonight alongside a $69 billion two-year note auction, the first leg of $183 billion of Treasury supply this week.

Author Suzie

Sep 22, Tue

The dollar index closed at 100.43 on Monday, its highest close since late July, after a weekly gain of about 1% — the best in more than three months — and is holding above the 100.00 handle in Asia. Three Fed officials speak tonight alongside a $69 billion two-year note auction, the first leg of $183 billion of Treasury supply this week.

October hike odds climb toward 60% as Goldman and BofA both flip — what Warsh's "dose of accommodation" really changed Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.

Author Irene Q.

Sep 23, Wed

Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.

Memory chips surge, Nasdaq notches a second straight record close — why the Dow fell 185 points anyway Micron gained 5%, SanDisk 6.8%, Seagate 4% and Western Digital 3% as the memory complex led the Nasdaq Composite to a second consecutive record close of 27,244.28. But the Dow fell 185 points as JPMorgan, Wells Fargo and Schwab slid more than 3% each — a split tape that says more about positioning than about the economy.

Author Irene Q.

Sep 23, Wed

Micron gained 5%, SanDisk 6.8%, Seagate 4% and Western Digital 3% as the memory complex led the Nasdaq Composite to a second consecutive record close of 27,244.28. But the Dow fell 185 points as JPMorgan, Wells Fargo and Schwab slid more than 3% each — a split tape that says more about positioning than about the economy.

US input costs rose at the fastest pace in four years — the September flash PMI beat is an inflation story, not a growth story US September flash PMIs came in far above expectations, with the composite at 58.4, a five-year high. But the detail that moved markets was input cost inflation at its fastest since October 2022, driven by fuel, transport and supply shortages. Brent is back above $100 and the 10-year Treasury yield has hit its highest since 2007.

Author Suzie

Sep 24, Thu

US September flash PMIs came in far above expectations, with the composite at 58.4, a five-year high. But the detail that moved markets was input cost inflation at its fastest since October 2022, driven by fuel, transport and supply shortages. Brent is back above $100 and the 10-year Treasury yield has hit its highest since 2007.

WTI (USOIL) Is down 2.03% on Sep 25: Here Is Why WTI (USOIL) is down 2.03% at Sep 24 22:20(UTC+0), now at $92.517, with a 7-day down of 3.63%.What is driving WTI (USOIL)’s stock price down today?The drop in WTI crude oil prices was primarily driven by

Author TradingKey

Sep 25, Fri

WTI (USOIL) is down 2.03% at Sep 24 22:20(UTC+0), now at $92.517, with a 7-day down of 3.63%.What is driving WTI (USOIL)’s stock price down today?The drop in WTI crude oil prices was primarily driven by

Popular Symbols